Deruxtecananalog是连接桥与药物的偶联物，是抗体-药物偶联物(ADC)的一部分。详细信息请参考专利文献WO2017002776A1中的化合物1。
货号:ajcx12862
CAS:N/A
分子式:N/A
分子量：N/A
溶解度:DMSO : ≥ 50 mg/mL (48.35 mM);H2O :< 0.1 mg/mL (insoluble)
纯度：98%
存储：Store at -20°C
库存：现货

Background:

Deruxtecan analog is a drug-linker conjugate for antibody-drug conjugate (ADC) extracted from patent WO2017002776A1, compound 1.

Antibody-drug conjugates deliver anticancer agents selectively and efficiently to tumor tissue and have significant antitumor efficacy with a wide therapeutic window[2].

[1]. NOGUCHI, Shigeru, et al. METHOD FOR SELECTIVELY MANUFACTURING ANTIBODY-DRUG CONJUGATE. WO2017002776A1. [2]. Ogitani Y, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107(7):1039-46.